International Journal of Clinical Research

Objective To explore the application significance of levosimendan in the treatment of elderly patients with pulmonary hypertension. Methods A retrospective analysis was conducted on the data of 100 elderly patients with pulmonary arterial hypertension admitted to our hospital from January 2021 to January 2025. The patients were divided into a control group (n=50) and a study group (n=50) according to different treatment plans. The control group received routine symptomatic treatment, while the study group received additional treatment with levosimendan. Data from both treatment groups were collected to analyze the effectiveness of different treatment strategies. Results Before treatment, there was no significant difference in various indicators between the two groups of patients (P>0.05); After treatment, compared with the control group, the lower limb circumference and pulmonary artery pressure were smaller in the study group, while 24-hour urine output and PaO2 levels were higher (P<0.05); After treatment, compared with the control group, the study group had a longer 6-minute walking distance and a lower MLHFQ score (P<0.05); There was no significant difference in the incidence of adverse reactions between the two groups of patients (P>0.05). Conclusion The use of levosimendan in the treatment of elderly patients with pulmonary arterial hypertension can achieve satisfactory results, help reduce pulmonary artery pressure, improve quality of life, and is safe and reliable. It is worthy of clinical promotion and application.

Zuo Ximengdan; Elderly pulmonary arterial hypertension; Treatment; Effect